DRD2 and glioblastoma: Adenosine A2A receptor‐targeting minor molecule antagonist AZD4635 and ONC201, an imipramine that antagonizes the dopamine receptor D2 (DRD2) and has demonstrated efficacy in glioblastoma in phase II trials, are noteworthy examples [303].